Pfizer (PFE): what its SEC filings show

Two years of results through Q3 2026 (Jul–Sep 2026), in plain English. Every figure links to the SEC filing it came from.

Built by the Tribune's code from SEC filings. No AI wrote or changed any figure. No ratings or advice. Updated Nov. 3, 2026. Latest report: 10-Q, filed Nov. 3, 2026. Updates automatically when the company files its next report. How this page works

The latest quarter at a glance

Revenue

$16.6B

unchanged from a year earlier

Q3 2025: $16.7B

Net income

$3.2B

down 8% from a year earlier

Q3 2025: $3.5B

Free cash flow

$4.8B

Q3 2025: $4.0B. Calculated by the Tribune

Shares outstanding

5.70B

unchanged from a year earlier

Q3 2025: 5.69B. More shares means each share owns a smaller slice

Q3 2026 (Jul–Sep 2026) compared with Q3 2025.

What changed this quarter

Revenue was $16.6 billion, unchanged from $16.7 billion a year earlier. Source
Net income was $3.2 billion, down 8% from $3.5 billion a year earlier. Source
Cash and short-term investments rose to $10.9 billion from $8.3 billion three months earlier. Source

Two-year trends

Revenue

All the money the company took in from sales, before any costs.

Billions of dollars, as filed.

Net income

What was left after all costs, interest and taxes: the bottom line. Below the line is a loss.

Billions of dollars: net income attributable to the company's shareholders, as filed (GAAP).

Free cash flow

Cash brought in by running the business, minus spending on property and equipment. Below the line means the company spent more than it brought in that quarter.

Billions of dollars. Calculated by the Tribune: cash from operations minus payments for property and equipment, both as filed.

Shares outstanding

How many shares exist. When the number rises, each share owns a smaller slice of the company.

Billions of shares on each quarter-end date (or on the report's cover page a few weeks later).

Cash and short-term investments compared with debt

Cash on hand next to what the company owes in loans and bonds.

Cash and short-term investmentsDebt

Billions of dollars at each quarter-end. Debt = short-term plus long-term debt, only when both are filed for that date (calculated by the Tribune). A dash means no data.

Warning-sign checks

Code looks for these filings in the last three years and reports only that a filing exists, never what it means for the stock.

Auditor change

The company changed the accounting firm that checks its books.

None in the last three years

Past results can't be relied on

The company said earlier reported results were wrong and will be corrected.

None in the last three years

Late filing

The company told the SEC a required report would be late.

None in the last three years

Every figure and its filing

Each figure links to the 10-Q or 10-K it came from. "No data" means it wasn't filed in a form the methodology accepts; nothing is estimated.

Figure	Q4 2024Oct–Dec 2024	Q1 2025Jan–Mar 2025	Q2 2025Apr–Jun 2025	Q3 2025Jul–Sep 2025	Q4 2025Oct–Dec 2025	Q1 2026Jan–Mar 2026	Q2 2026Apr–Jun 2026	Q3 2026Jul–Sep 2026
Revenue	$17.8 billion	$13.7 billion	$14.7 billion	$16.7 billion	$17.6 billion	$14.5 billion	$15.0 billion	$16.6 billion
Net income	$410 million	$3.0 billion	$2.9 billion	$3.5 billion	−$1.6 billion	$2.7 billion	−$248 million	$3.2 billion
Cash from operations	$6.7 billion	$2.3 billion	−$582 million	$4.6 billion	$5.3 billion	$2.6 billion	$835 million	$5.4 billion
Spending on property and equipment	$917 million	$564 million	$618 million	$602 million	$845 million	$436 million	$533 million	$573 million
Free cash flow (calculated)	$5.8 billion	$1.8 billion	−$1.2 billion	$4.0 billion	$4.5 billion	$2.2 billion	$302 million	$4.8 billion
Gross margin (calculated)	No data	No data	No data	No data	No data	No data	No data	No data
Shares outstanding	5.67 billion	5.69 billion	5.69 billion	5.69 billion	5.69 billion	5.70 billion	5.70 billion	5.70 billion
Cash and short-term investments (calculated)	$11.9 billion	$15.4 billion	$11.2 billion	$11.5 billion	$10.3 billion	$9.9 billion	$8.3 billion	$10.9 billion
Debt (calculated)	$64.4 billion	$62.1 billion	$61.8 billion	$61.7 billion	$64.8 billion	$64.5 billion	$63.2 billion	$62.7 billion

Want an alert when Pfizer files something important?

Alerts aren't available yet. Tap the button if you'd use them. It only adds one to a count: no email, no sign-up.

Figures as filed in 10-Q and 10-K reports; the latest filing wins. Single quarters, the fourth quarter (the full year minus the first nine months), free cash flow, margins and changes are calculated by the Tribune. Methodology version 1.2. How this page works · All of Pfizer's filings on SEC EDGAR